Clinical Trial

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy

Enrolling by Invitation Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 21, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of EXG001-307 as a treatment of spinal muscular atrophy .
Trial Details
NCT Number NCT06888661
Lead Sponsor Guangzhou Jiayin Biotech Ltd
Conditions Spinal Muscular Atrophy (SMA)
Enrollment 4 participants
Start Date 2025-03-10
Primary Completion 2026-03 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-21